<?xml version='1.0' encoding='utf-8'?>
<document id="30559132"><sentence text="Mass Balance and Drug Interaction Potential of Intravenous Eravacycline Administered to Healthy Subjects."><entity charOffset="59-71" id="DDI-PubMed.30559132.s1.e0" text="Eravacycline" /></sentence><sentence text="Eravacycline is a novel, fully synthetic fluorocycline that is approved for the treatment of complicated intra-abdominal infections (cIAI) in adult patients"><entity charOffset="0-12" id="DDI-PubMed.30559132.s2.e0" text="Eravacycline" /><entity charOffset="41-54" id="DDI-PubMed.30559132.s2.e1" text="fluorocycline" /><pair ddi="false" e1="DDI-PubMed.30559132.s2.e0" e2="DDI-PubMed.30559132.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30559132.s2.e0" e2="DDI-PubMed.30559132.s2.e1" /></sentence><sentence text=" We report results from three studies in healthy subjects that investigated the distribution, metabolism, and excretion of intravenous (i" /><sentence text="v" /><sentence text=") eravacycline and the effect of a CYP3A4 inhibitor (itraconazole) and inducer (rifampin) on the pharmacokinetics (PK) of i"><entity charOffset="2-14" id="DDI-PubMed.30559132.s5.e0" text="eravacycline" /><entity charOffset="53-65" id="DDI-PubMed.30559132.s5.e1" text="itraconazole" /><entity charOffset="80-88" id="DDI-PubMed.30559132.s5.e2" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.30559132.s5.e0" e2="DDI-PubMed.30559132.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30559132.s5.e0" e2="DDI-PubMed.30559132.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30559132.s5.e0" e2="DDI-PubMed.30559132.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30559132.s5.e1" e2="DDI-PubMed.30559132.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30559132.s5.e1" e2="DDI-PubMed.30559132.s5.e2" /></sentence><sentence text="v" /><sentence text=" eravacycline"><entity charOffset="1-13" id="DDI-PubMed.30559132.s7.e0" text="eravacycline" /></sentence><sentence text=" In the mass balance study, the majority of total radioactivity from [14C]eravacycline was recovered in the feces, suggesting biliary/fecal elimination is the major route of excretion for eravacycline and its metabolites after IV administration"><entity charOffset="69-86" id="DDI-PubMed.30559132.s8.e0" text="[14C]eravacycline" /><entity charOffset="188-200" id="DDI-PubMed.30559132.s8.e1" text="eravacycline" /><pair ddi="false" e1="DDI-PubMed.30559132.s8.e0" e2="DDI-PubMed.30559132.s8.e0" /><pair ddi="false" e1="DDI-PubMed.30559132.s8.e0" e2="DDI-PubMed.30559132.s8.e1" /></sentence><sentence text=" The volume of distribution (217 liters) was greater than that of extracellular fluid, which suggests distribution beyond the central compartment" /><sentence text=" In the drug-drug interaction studies, mean area under the concentration-time curve from 0 h to the last time point (AUC0&#10;                        -t&#10;                     ) and half-life were increased approximately 30% to 40% after a concomitant dose of i" /><sentence text="v" /><sentence text=" eravacycline and itraconazole and clearance (CL) was decreased"><entity charOffset="1-13" id="DDI-PubMed.30559132.s12.e0" text="eravacycline" /><entity charOffset="18-30" id="DDI-PubMed.30559132.s12.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.30559132.s12.e0" e2="DDI-PubMed.30559132.s12.e0" /><pair ddi="false" e1="DDI-PubMed.30559132.s12.e0" e2="DDI-PubMed.30559132.s12.e1" /></sentence><sentence text=" A reduction in total eravacycline exposure (AUC) of approximately 25% to 35% and an increase in CL of approximately 50% occurred with concomitant eravacycline and rifampin treatment"><entity charOffset="22-34" id="DDI-PubMed.30559132.s13.e0" text="eravacycline" /><entity charOffset="147-159" id="DDI-PubMed.30559132.s13.e1" text="eravacycline" /><entity charOffset="164-172" id="DDI-PubMed.30559132.s13.e2" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.30559132.s13.e0" e2="DDI-PubMed.30559132.s13.e0" /><pair ddi="false" e1="DDI-PubMed.30559132.s13.e0" e2="DDI-PubMed.30559132.s13.e1" /><pair ddi="false" e1="DDI-PubMed.30559132.s13.e0" e2="DDI-PubMed.30559132.s13.e2" /><pair ddi="false" e1="DDI-PubMed.30559132.s13.e1" e2="DDI-PubMed.30559132.s13.e1" /><pair ddi="false" e1="DDI-PubMed.30559132.s13.e1" e2="DDI-PubMed.30559132.s13.e2" /></sentence><sentence text=" The dose of eravacycline should be increased to 1"><entity charOffset="13-25" id="DDI-PubMed.30559132.s14.e0" text="eravacycline" /></sentence><sentence text="5 mg/kg of body weight every 12 h when coadministered with a strong CYP3A inducer" /><sentence text="" /></document>